Outcomes of surgical bioprosthetic aortic valve replacement in patients ≤65 and >65 years of age
Recommended Citation
Kiaii BB, Moront MG, Patel HJ, et al. Outcomes of Surgical Bioprosthetic Aortic Valve Replacement in Patients Aged ≤65 and >65 Years. Ann Thorac Surg. 2023;116(3):483-490. doi:10.1016/j.athoracsur.2021.12.057
Abstract
BACKGROUND: Implantation of a bioprosthetic valve is a reasonable choice for patients aged >65 years. For middle-aged patients, there is less certainty about whether a mechanical or bioprosthetic valve is best. METHODS: The PERIcardial SurGical AOrtic Valve ReplacemeNt (PERIGON) Pivotal Trial is evaluating the safety and efficacy of the Avalus bioprosthesis. We evaluated clinical and echocardiographic outcomes through 5 years of follow-up, stratified by age ≤65 and >65 years. RESULTS: Two hundred seventy-one patients (24.2%) were ≤65 years old, and 847 (75.8%) were >65 years old. Most patients in both groups were male (217 [80.1%] vs 623 [73.6%], respectively; p=0.031). Younger patients had a lower STS risk of mortality (1.1±0.9% vs 2.2±1.4%, p65 years of age.
Document Type
Article
PubMed ID
35065064
Affiliations
Aurora St. Luke's Medical Center